Identification of a novel missense mutation in the TPM1 gene via exome sequencing in a Chinese family with dilated cardiomyopathy

A case report and literature review

Yilong Man, MSa,b, Changying Yi, BSb, Meili Fan, MSD, Tianyu Yang, MDe, Peng Liu, BSa, Shiguang Liu, BSf, Guangxin Wang, MD, PhDg,h,*

Abstract

definitions:

Rationale: Dilated cardiomyopathy (DCM) is a cardiovascular disorder characterized by consecutive ventricular dilation and contractile dysfunction, often leading to congestive heart failure. DCM type 1Y (DCM1Y) is caused by a mutation in the TPM1 (tropomyosin 1) gene. To date, about thirty TPM1 gene mutations have been reported to be related to DCM1Y. However, mutational screening of the TPM1 gene is still far from being complete. Identification of TPM1 mutation is particularly important in the diagnosis of DCM1Y and will give more insights into the molecular pathogenesis of DCM1Y.

Patient concerns: A Chinese Han family with DCM phenotypes was examined.

Diagnosis: A novel missense mutation, c.340G>C in exon 3 of the TPM1 gene, was identified.

Interventions: Next-generation sequencing (NGS) of DNA samples was performed to detect the gene mutation in the proband, which was confirmed by Sanger sequencing.

Outcomes: This novel heterozygous mutation results in the substitution of glutamic acid with glutamine (p.E114Q). Based on this finding and clinical manifestations, a final diagnosis of DCM1Y was made.

Lessons: We present evidence that p.E114Q mutation represents a novel TPM1 mutation in a Chinese Han family with DCM. Our data expand the mutation spectrum of the TPM1 gene and may facilitate the clinical diagnosis of DCM1Y.

Abbreviations: DCM = dilated cardiomyopathy, DCM1Y = DCM, type 1Y, ECG = electrocardiogram, NGS = next-generation sequencing, TPM1 = tropomyosin 1.

Keywords: dilated cardiomyopathy, echocardiography, missense mutation, next-generation sequencing, tropomyosin 1 gene

1. Introduction

Dilated cardiomyopathy (DCM) is a cardiovascular disorder characterized by consecutive ventricular dilation and contractile dysfunction, with an incidence of about 1 in 2500 individuals.[1–3] Due to its significant prevalence, high morbidity and mortality, and the frequent hospitalization it causes, DCM is a major health issue for adults. The causes of DCM are heterogeneous, such as myocarditis, exposure to drugs, alcohol, or other toxins, and metabolic or endocrine disturbances. Genetic mutations that usually involve genes responsible for cytoskeletal, sarcomere, and nuclear envelope proteins can be identified in 30% to 40% of DCM cases.[4,5] Due to the heterogeneity of DCM causes, a detailed diagnostic work-up is necessary to identify the specific underlying cause and exclude other conditions with phenotype overlap.[6]

Genetic studies have so far identified 42 different forms of DCM caused by mutations in more than 40 genes, such as the lamin A (LMNA), desmoglein 2 (DSG2), and tropomyosin 1 (TPM1) genes. Additionally, some of these genes that harbor DCM mutations are very large. Hence, examining all coding exons and intron/exon junctions for variations in multiple genes is expensive and labor-intensive. Next-generation sequencing (NGS) has been used as an alternative approach to more traditional methods for detecting gene mutations. NGS has many advantages; it not only produces massive amounts of data in parallel but also measures each base pair to an unprecedented
was performed on a DNA thermal cycler (Gene Amp 9700, Perkin-Elmer, USA) with the 2 × Hotstart Taq PCR Mastermix kit (Tiangen Biotech Beijing Co. LTD., China). In a 50mL reaction mix, 300 ng of genomic DNA was used with 2.0mL of each primer (10 mmol/L) and 25 mL of the 2 × PCR Mastermix. Genomic DNA was first denatured at 95°C for 5 minutes, followed by 25 cycles of 95°C for 30 seconds, 65°C (−0.6°C/cycle) for 30 seconds, 72°C for 40 seconds, and then 20 cycles of 95°C for 30 seconds, 50°C for 30 seconds, 72°C for 40 seconds. The PCR products were extended at 72°C for 10 minutes. The products were gel-purified with an agarose gel DNA purification kit (Tiangen Biotech Beijing Co. LTD., China), and the purified PCR products were sequenced using the forward and reverse primers. Automated sequencing was performed at both ends on an ABI 377 automated sequencer. Mutations were interpreted according to the American College of Medical Genetics and Genomics (ACMG) recommended standard.[9]

2.2.3. In silico analysis. After novel missense mutations were identified, in silico analyses were performed using 2 web-based tools, namely Polymorphism Phenotyping v2 (PolyPhen-2) and Sorting Intolerant from Tolerant (SIFT), to assess the deleterious effects of these newly detected mutations on the function of the TPM1. PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/) predicts the potential impact of an amino acid substitution on the structure and function of a human protein using straightforward comparative analyses of structural attributes of the mutated protein. PolyPhen-2 predicted3 possible outcomes of these mutations, based on scores ranging from 0 to 1, which were as follows: probably damaging, possibly damaging, or benign. SIFT (http://sift.bii.a-star.edu.sg/) is a sequences homology-based tool, which predicts the important amino acids that are conserved in a protein family. In this study, the results were expressed as SIFT scores, which were classified as damaging (0.00–0.05), potentially damaging (0.051–0.10), borderline (0.101–0.20), or tolerant (0.201–1.00).

3. Results
3.1. Clinical data
The proband’s vital signs were stable on admission, and physical examination showed an enlarged left cardiac dullness border with a high heart rate (113 bpm). Laboratory tests were normal except for a slightly elevated neuron-specific enolase (24.11ng/mL). The electrocardiogram showed ST-T wave changes and nodal tachycardia (Fig. 1B). Echocardiography revealed a left ventricular end-diastolic diameter of 27 mm/m² and an ejection fraction <40% or fractional shortening <25% in the absence of abnormal loading conditions, coronary artery disease, congenital heart lesions, and other systemic diseases.[8]

2. Methods
2.2. NGS. NGS was performed on the proband (II-1).

2.2.2. Sanger sequencing. To validate the positive mutations identified via exome sequencing, Sanger sequencing was performed to confirm the presence or absence of these mutations in the proband, unaffected family members, and 50 unrelated healthy controls.

Specific PCR primers (forward primer 5’-TCTCCCCAACTC-TGAAATGC-3’, reverse primer 5’- GGCTTAGGACAGT-GCTTTTG-3’) were used for the amplification of exon 3 in the TPM1 gene based on the reference sequences of the human genome from GenBank in NCBI (Gene ID: 7168). PCR cycling depth, greatly reducing the time and cost of sequencing each sample at each locus.[7]

In this study, we described the clinical, echocardiographic, and electrocardiogram (ECG) characteristics of a Chinese Han family with DCM. We used a NGS-based method to identify a novel missense mutation, c.340G>C in exon 3 of the TPM1 gene, in this family. Patients in this family were diagnosed as DCM type 1Y (DCM1Y).

2. Patients and methods
2.1. Proband and family investigation
Figure 1A shows the pedigree of the DCM family. The proband (II-1) was a 40-year-old Chinese Han male born at full term after an uncomplicated pregnancy and delivery. He was admitted for chest tightness and abdominal distension for 1 month. His symptoms worsened for 4 days and were accompanied by dyspnoea. His past medical history was unremarkable; he was without metabolic disorders, premature aging, or skeletal muscle disease. His mother had the same symptoms of chest tightness, dyspnoea, and abdominal distension and died of DCM at the age of 50 years. All available individuals with or without a positive history were evaluated via a full physical examination, chest radiography, echocardiography, and ECG. Medical records were reviewed in the case of deceased relatives. DCM was defined according to the criteria established by the World Health Organization/International Society and Federation of Cardiology Task Force on the Classification of Cardiomyopathy: a left ventricular end-diastolic diameter >27 mm/m² and an ejection fraction <40% or fractional shortening <25% in the absence of abnormal loading conditions, coronary artery disease, congenital heart lesions, and other systemic diseases.[8]

This work was approved by the ethics committee of the central hospital affiliated to Shandong First Medical University. Written informed consent was obtained from all participants before the study. The proband has provided informed consent for publication of the case.

This study, 19 variants in 18 genes were detected using NGS. We then excluded those variants with an allele frequency of more than 5% in the dbSNP database, 1000 human genome dataset, exome aggregation consortium (ExAC), and genome aggregation database (gnomAD). According to the detailed filtering criteria and analysis pipeline published before,[9] a missense mutation, c.340G>C in exon 3 of the TPM1 gene, was revealed in the proband. This mutation was then confirmed by Sanger sequencing (Fig. 2). This heterozygous mutation results in the

2.2. Methods
2.2.1. NGS. NGS was performed on the proband (II-1).

2mL of peripheral blood was drawn into K2-EDTA tubes and stored at 4°C for a maximum of 24 hours. Genomic DNA was extracted from the blood using the TIANamp Blood DNA Kit (Tiangen Biotech Beijing Co. LTD., China). After DNA isolation, 1 µg genomic DNA was fragmented into about 200bp lengths using the Covaris Acoustic System. The DNA fragments were stored at 4°C. The genomic DNA was around 43.1%, and a fractional shortening of 21.7% was performed on a DNA thermal cycler (Gene Amp 9700, Perkin-Elmer, USA) with the 2 × Hotstart Taq PCR Mastermix kit (Tiangen Biotech Beijing Co. LTD., China). In a 50mL reaction mix, 300 ng of genomic DNA was used with 2.0mL of each primer (10 mmol/L) and 25 mL of the 2 × PCR Mastermix. Genomic DNA was first denatured at 95°C for 5 minutes, followed by 25 cycles of 95°C for 30 seconds, 65°C (−0.6°C/ cycle) for 30 seconds, 72°C for 40 seconds, and then 20 cycles of 95°C for 30 seconds, 50°C for 30 seconds, 72°C for 40 seconds. The PCR products were extended at 72°C for 10 minutes. The products were gel-purified with an agarose gel DNA purification kit (Tiangen Biotech Beijing Co. LTD., China), and the purified PCR products were sequenced using the forward and reverse primers. Automated sequencing was performed at both ends on an ABI 377 automatic sequencer. Mutations were interpreted according to the American College of Medical Genetics and Genomics (ACMG) recommended standard.[9]
substitution of glutamic acid with glutamine (p.E114Q). No mutation at this site was found in available unaffected family members or 50 unaffected, unrelated healthy controls. According to the HGMD (http://www.hgmd.cf.ac.uk/docs/login.html), this heterozygous mutation is novel. Homology analysis of the p. E114 site in different animal species indicated that this amino acid is highly conserved (Table 1), which supports the possibility that this mutation is pathogenic.

3.3. In silico analysis

The results of PolyPhen-2 and SIFT analysis of c.340G>C in exon 3 of the TPM1 gene further provided conclusive evidence that this mutation is the cause of the clinical phenotype. This mutation was predicted to be probably damaging by Poly Phen-2 (score = 0.962) and deleterious by SIFT (score = 0.01).

Taken together, the diagnosis of DCM1Y was made by considering the clinical, echocardiographic, and ECG characteristics, as well as genetic testing. The patient was treated with metoprolol (23.75 mg, qd, po). He reported alleviation of symptoms at 1-year follow-up and is still on our follow-up list.

4. Discussion

DCM is the third most common cause of congestive heart failure and a major indication for heart transplantation. Patients with DCM are often first sent to the hospital for intermittent chest tightness upon physical or emotional stress. Conventionally, the
diagnosis of DCM is established by echocardiography. In the present study, a missense mutation in a Chinese Han family with DCM is reported. The patients had typical features of DCM. Echocardiography of the proband showed a left ventricular end-diastolic diameter of 33.6 mm/m², an ejection fraction of 43.1%, and a fractional shortening of 21.7%, consistent with the criteria for diagnosing DCM proposed by the World Health Organization and a fractional shortening of 21.7%, consistent with the criteria for diagnosing DCM proposed by the World Health Organization.

To date, about thirty mutations, including missense mutation, frameshift mutation due to deletion, and nonsense mutation (Table 2), have been reported in the TPM1 gene for DCM in Pubmed, Embase, Web of Science, and the Human Gene Mutation Database (HGMD, http://www.hgmd.org/). The mutational screening of the TPM1 gene is still far from complete. Identifying more novel mutations will provide more insights into the molecular pathogenesis of DCM. The mutation c.340G>C found in this research is a missense mutation. After searching the SNP database and the human gene mutation database, we found that this mutation was absent from these databases. This suggests that this Chinese Han family carries a novel heterozygous mutation.

5. Conclusion
Based on the results, we present evidence that p.E114Q mutation represents a novel TPM1 mutation in a Chinese Han family with DCM1Y. Our data extend the mutation spectrum of the TPM1 gene, provide new insights into the molecular basis for the pathogenesis of DCM and may aid early diagnosis.

Acknowledgments
We thank the patients and their family members for their cooperation in this study. This work was supported by science and technology project of Jinan health commission (2020-3-02),
and Shandong provincial natural science foundation (No. ZR2019MH043).

**Author contributions**

Data curation: Yilong Man, Guangxin Wang.

Formal analysis: Meili Fan, Changying Yi, Guangxin Wang.

Funding acquisition: Changying Yi, Guangxin Wang.

Investigation: Yilong Man, Tianyu Yang, Peng Liu, Shiguang Liu.

Project administration: Changying Yi, Guangxin Wang.

Resources: Tianyu Yang, Peng Liu, Guangxin Wang.

Software: Meili Fan, Shiguang Liu.

Supervision: Changying Yi, Guangxin Wang.

Writing – original draft: Yilong Man, Meili Fan.

Writing – review & editing: Changying Yi, Guangxin Wang.

**References**

[1] Reichart D, Magnussen C, Zeller T, Blankenberg S. Dilated cardiomyopathy: from epidemiologic to genetic phenotypes: a translational review of current literature. J Intern Med 2019;286:362–72.

[2] Taylor MR, Carniel E, Mestroni L. Cardiomyopathy, familial dilated. Orphanet J Rare Dis 2006;1:27.

[3] Tharp CA, Haywood ME, Sbaizero O, Taylor MRG, Mestroni L. The giant protein Titin’s role in cardiomyopathy: genetic, transcriptional, and post-translational modifications of TTN and their contribution to cardiac Disease. Front Physiol 2019;10:1436.

[4] Hershberger RE, Morales A, Siegfried JD. Clinical and genetic issues in dilated cardiomyopathy: a review for genetics professionals. Genet Med 2010;12:655–67.

[5] Merlo M, Cannatà A, Gobbo M, Stolfò D, Elliott PM, Sinagra G. Evolving concepts in dilated cardiomyopathy. Eur J Heart Fail 2018;20:228–39.

[6] Duboscq-Bidot L, Xu P, Charron P, et al. Mutations in the Z-band protein myopalladin gene and idiopathic dilated cardiomyopathy. Cardiovasc Res 2008;77:118–25.

[7] Yao G, Wang G, Wang D, Su G. Identification of a novel mutation of FGFR3 gene in a large Chinese pedigree with hypochondroplasia by next-generation sequencing: a case report and brief literature review. Medicine (Baltimore) 2019;98:e14137.

[8] Xu YJ, Wang ZS, Yang CX, et al. Identification and functional characterization of an ISL1 mutation predisposing to dilated cardiomyopathy. J Cardiovasc Transl Res 2019;12:257–67.

[9] Li MM, Dattu M, Duncavage EJ, et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn 2017;19:4–23.

[10] Wei X, Ju X, Yi X, et al. Identification of sequence variants in genetic disease-causing genes using targeted next-generation sequencing. PLoS One 2011;6:e29500.

[11] Zhang M, Chen J, Si D, et al. Whole exome sequencing identifies a novel EMD mutation in a Chinese family with dilated cardiomyopathy. BMC Med Genet 2014;15:77.

[12] Sammani A, Baas AF, Asselbergs FW, Te Riele ASJM. Diagnosis and risk prediction of dilated cardiomyopathy in the era of big data and genomics. J Clin Med 2021;10:921.

[13] Jia S, Ma WD, Zhang CY, et al. Tanshinone IIa attenuates high glucose induced human VSMC proliferation and migration through miR-21-5p mediated troponyosin 1 downregulation. Arch Biochem Biochem 2019;677:108154.

[14] Walsh R, Thomson KL, Ware JS, et al. Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples. Genet Med 2017;19:192–203.

[15] Lakdawala NK, Funke BH, Baxter S, et al. Genetic testing for dilated cardiomyopathy in clinical practice. J Card Fail 2012;18:296–303.

[16] Hershberger RE, Norton N, Morales A, Li D, Siegfried JD, Gonzalez-Quintana J. Coding sequence rare variants identified in MYBPC3, MYH6, TPM1, TNNT1, and TNNT3 from 312 patients with familial or idiopathic dilated cardiomyopathy. Circ Cardiovasc Genet 2010;3:155–61.

[17] Olson TM, Kishimoto NY, Whitey FG, Michels VV. Mutations that alter the surface charge of alpha-tropomyosin are associated with dilated cardiomyopathy. J Mol Cell Cardiol 2001;33:723–32.

[18] Pugh TJ, Kelly MA, Gowerisankar S, et al. The landscape of genetic variation in dilated cardiomyopathy as surveyed by clinical DNA sequencing. Genet Med 2014;16:601–8.

[19] van de Meerakker JB, Christaans I, Barnett P, et al. A novel alpha-tropomyosin mutation associates with dilated and non-compaction cardiomyopathy and diminishes actin binding. Biochim Biophys Acta 2013;1833:833–9.

[20] Colpan M, Ly T, Grover S, Tolkatchev D, Kostyukova AS. The cardiomyopathy-associated K15N mutation in tropomyosin alters filament pointed end dynamics. Arch Biochem Biochem 2017;630:18–26.

[21] van Spaendonck-Zwarts KY, van Ruijsen IA, van den Berg MP, et al. Genetic analysis in 418 index patients with idiopathic dilated cardiomyopathy: overview of 10 years’ experience. Eur J Heart Fail 2013;15:628–36.

[22] Franaszczuk M, Truszkiowska G, Chmielewski P, et al. Analysis of de novo mutations in sporadic cardiomyopathies emphasizes their clinical relevance and points to novel candidate genes. J Clin Med 2020;9:570.

[23] Lakdawala NK, Dellefave L, Redwood CS, et al. Familial dilated cardiomyopathy caused by an alpha-tropomyosin mutation: the distinctive natural history of sarcomeric dilated cardiomyopathy. J Am Coll Cardiol 2010;55:320–9.

[24] Wilson KD, Shen P, Fung E, et al. A rapid, high-quality, cost-effective, comprehensive and expandable targeted next-generation sequencing assay for inherited heart diseases. Circ Res 2015;117:603–11.